Danish pharma major Novo Nordisk has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for once-weekly CagriSema (cagrilintide and semaglutide) injection, to be used ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback